Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree - 2At least 36 dead in major fire in Hong Kong residential blocks
- 3Bombardier Global 8000 Enters Service
- 4Let them eat (Taylor Swift) cake: The baker turning A-listers into life-size desserts
- 5Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- New subclade K flu strain raises concerns: What families should know
- Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
- Massive supernova explosion may have created a binary black hole
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- Day to day Temporary Positions That Compensate Fairly in the US
- Scientists captured female sperm whales on video working together during a birth to protect the calf
- Scientists have found an alarming environmental impact of vast data centers
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Europe could get 42 more days of summer by the year 2100 due to climate change
